Quantcast

Latest BioTrends Research Group Inc. Stories

2010-12-21 09:15:00

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan's Tysabri. Prescribing of both Tysabri and Novartis's recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer's Betaferon suffering the most in...

2010-12-21 09:15:00

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report focused on the management and treatment of systemic lupus erythematosus (SLE) in the U.S. ChartTrends®: Systemic Lupus Erythematosus is an annual publication based on patient and laboratory data collected from 1,079 lupus patient charts as submitted by 201 rheumatologists. The report provides insight into the factors that drive...

2010-12-20 09:00:00

EXTON, Pa., Dec. 20, 2010 /PRNewswire/ -- In its recently released annual 2010 update, ChartTrends®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer biologic agents such as UCB's Cimzia and Centocor OrthoBiotech's Simponi, although lagging in overall market share, have begun to penetrate the first line biologic position primarily at the expense of Pfizer/Amgen's Enbrel and Abbott's Humira. In a comparison of rheumatoid arthritis (RA)...

2010-12-13 09:45:00

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that on most metrics, perceptions of Acorda's Ampyra, the first FDA-approved product for the management of a multiple sclerosis (MS) symptom, have remained consistent or improved since earlier waves, including product awareness, interest, satisfaction, the managed care process and Acorda's patient support program. Compared to early in the launch, patient requests play a less impactful role in Ampyra uptake. With...

2010-12-13 09:45:00

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that with the introduction of Novartis' Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate major shifts in the landscape of the MS market. One month after the launch of Gilenya, trial and uptake of Extavia, a DMA launched by Novartis one year earlier, continues to be tempered due to the perception that Extavia is a "me too" agent -a...

2010-12-08 07:00:00

EXTON, Pa., Dec. 8, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that although Allopurinol remains the gold standard uric acid lowering (UAL) therapy for gout in the European Union (EU), Teijin Pharma/Ipsen/Menarini's Adenuric (currently available in France, Germany and the United Kingdom) has already achieved significant market penetration. The uptake of Adenuric is particularly robust in France, where its patient share is approximately one-half that of Allopurinol in...

2010-12-06 07:00:00

EXTON, Pa., Dec. 6, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by potential safety / tolerability concerns and monitoring requirements. The majority of surveyed neurologists indicate they are aware of Gilenya and -- even with already high levels of familiarity -- they remain interested in learning more about the product. As the first oral disease-modifying agent (DMA) to be...

2010-12-01 08:00:00

EXTON, Pa., Dec. 1, 2010 /PRNewswire/ -- BioTrends recently published TreatmentTrends®: Multiple Sclerosis, a syndicated biannual report that provides a comprehensive view of the current and expected future management of multiple sclerosis (MS) based on primary research fielded with 103 neurologists in the U.S. A parallel report covering the European market (EU5) will be published later this month. These reports cover the use of disease-modifying agents (DMAs) for the...

2010-11-29 11:40:00

EXTON, Pa., Nov. 29, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Bone and Mineral Metabolism in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 U.S. CKD-ND patient charts. This report both quantifies and characterizes CKD stage 3, 4 and 5 patients under the care of a nephrologist, identifying referral patterns, physician co-management, frequency of...

2010-11-23 07:00:00

EXTON, Pa., Nov. 23, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Renal Anemia in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 US CKD-ND patient charts. ChartTrends® compare what physicians self-report about disease management to what actually occurs at the patient level. This report evaluates the management of renal anemia...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'